Share This

Related Topics News - Drugs

     
 Title only   |   Print    Next page > 
     
金斯瑞斥2.25億美元增持CDMO服務附屬Probio Cayman

2025-04-28T  
金斯瑞生物科技甜味蛋白產品獲美國藥監局GRAS認證

2025-04-28T  
《大行》美銀證券升石藥目標價至5.1元 評級「跑輸大市」

2025-04-28T  
《業績》國藥首季賺14.57億人幣 按年升2.6%

2025-04-28T  
石藥集團新藥SYH2068注射液獲准開展臨床試驗

2025-04-27T  
國藥控股附屬國藥股份首季淨利潤微降至4.59億人民幣

2025-04-25T  
國藥控股附屬國藥一致首季淨利潤3.28億人民幣 倒退15.6%

2025-04-24T  
《業績》國藥控股附屬國藥器械首季營業利潤2.77億人幣 按年跌7.4%

2025-04-24T  
石藥集團附屬石藥創新第一季轉虧2,690萬人民幣

2025-04-23T  
石藥集團普盧格列汀二甲雙胍緩釋片臨床試驗獲批

2025-04-23T  
  Next page > 

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2025 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.